Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
SELLAS Life Sciences Group, Inc.
Report date September 24, 2018 · Filed September 26, 2018
Jointly reported with Lopez Fabio, EQC Private Markets SAC Fund II Ltd-EQC Biotech Sely S Fund, EQC Private Markets SAC Fund Ltd-EQC Biotech Sely I Fund, EQC Private Markets SAC Fund Ltd-EQC Biotech Sely II Fund`, Equilibria Capital Management Ltd, Varibobi Financial Holdings Ltd, Tafur Daniel, EQC Private Markets II SAC Fund Ltd-EQC Biotech Sely III Fund
Section 16 reporting ended · disclosed 2018-09-26. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-09-24 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2018-09-24 · Other · Disposed 1,521,863 · Balance 0 F1: EQC Private Markets SAC Fund II Ltd-EQC Biotech Sely S Fund ("Sely S") distributed 1,521,863 shares to its partners on a pro rata basis, for no consideration. F2: As a partner of Sely S, Fabio Lopez, received 19,524 of the shares distributed by Sely S. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-09-24 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2018-09-24 · Other · Disposed 676,324 · Balance 0 F3: EQC Private Markets SAC Fund Ltd-EQC Biotech Sely I Fund ("Sely I") distributed 676,324 shares to its partners on a pro rata basis, for no consideration. F4: As partners of Sely I, Daniel Tafur and Equilibria Capital Management received 13,871 and 107,619, respectively, of the shares distributed by Sely I. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-09-24 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2018-09-24 · Other · Disposed 325,799 · Balance 0 F5: EQC Private Markets SAC Fund Ltd-EQC Biotech Sely II Fund ("Sely II") distributed 325,799 shares to its partners on a pro rata basis, for no consideration. F6: As partners of Sely II, Fabio Lopez and Daniel Tafur received 6,325 and 2,372, respectively, of the shares distributed by Sely II. |
Filing footnotes · ownership attribution and instrument terms
F1: EQC Private Markets SAC Fund II Ltd-EQC Biotech Sely S Fund ("Sely S") distributed 1,521,863 shares to its partners on a pro rata basis, for no consideration.
F2: As a partner of Sely S, Fabio Lopez, received 19,524 of the shares distributed by Sely S.
F3: EQC Private Markets SAC Fund Ltd-EQC Biotech Sely I Fund ("Sely I") distributed 676,324 shares to its partners on a pro rata basis, for no consideration.
F4: As partners of Sely I, Daniel Tafur and Equilibria Capital Management received 13,871 and 107,619, respectively, of the shares distributed by Sely I.
F5: EQC Private Markets SAC Fund Ltd-EQC Biotech Sely II Fund ("Sely II") distributed 325,799 shares to its partners on a pro rata basis, for no consideration.
F6: As partners of Sely II, Fabio Lopez and Daniel Tafur received 6,325 and 2,372, respectively, of the shares distributed by Sely II.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 24, 2018 Filed Sep 26, 2018 19:43 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | OtherCommon Stock | 325,799 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-025346 · doc4.xml · nonDerivative · entry 3 Lopez Fabio · CIK 0001724449 · Former Director, 10% holder EQC Private Markets SAC Fund II Ltd-EQC Biotech Sely S Fund · CIK 0001724585 · 10% owner EQC Private Markets SAC Fund Ltd-EQC Biotech Sely I Fund · CIK 0001724529 · 10% owner EQC Private Markets SAC Fund Ltd-EQC Biotech Sely II Fund` · CIK 0001724530 · 10% owner Equilibria Capital Management Ltd · CIK 0001724701 · 10% owner Castilian Ltd. · CIK 0001724523 · 10% owner Varibobi Financial Holdings Ltd · CIK 0001724811 · 10% owner Tafur Daniel · CIK 0001724558 · 10% owner EQC Private Markets II SAC Fund Ltd-EQC Biotech Sely III Fund · CIK 0001724539 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F5 · kind: EQC Private Markets SAC Fund Ltd-EQC Biotech Sely II Fund ("Sely II") distributed 325,799 shares to its partners on a pro rata basis, for no consideration. F6 · balance_after: As partners of Sely II, Fabio Lopez and Daniel Tafur received 6,325 and 2,372, respectively, of the shares distributed by Sely II. Read SEC document |
| September 24, 2018 Filed Sep 26, 2018 19:43 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | OtherCommon Stock | 676,324 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-025346 · doc4.xml · nonDerivative · entry 2 Lopez Fabio · CIK 0001724449 · Former Director, 10% holder EQC Private Markets SAC Fund II Ltd-EQC Biotech Sely S Fund · CIK 0001724585 · 10% owner EQC Private Markets SAC Fund Ltd-EQC Biotech Sely I Fund · CIK 0001724529 · 10% owner EQC Private Markets SAC Fund Ltd-EQC Biotech Sely II Fund` · CIK 0001724530 · 10% owner Equilibria Capital Management Ltd · CIK 0001724701 · 10% owner Castilian Ltd. · CIK 0001724523 · 10% owner Varibobi Financial Holdings Ltd · CIK 0001724811 · 10% owner Tafur Daniel · CIK 0001724558 · 10% owner EQC Private Markets II SAC Fund Ltd-EQC Biotech Sely III Fund · CIK 0001724539 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F3 · kind: EQC Private Markets SAC Fund Ltd-EQC Biotech Sely I Fund ("Sely I") distributed 676,324 shares to its partners on a pro rata basis, for no consideration. F4 · balance_after: As partners of Sely I, Daniel Tafur and Equilibria Capital Management received 13,871 and 107,619, respectively, of the shares distributed by Sely I. Read SEC document |
| September 24, 2018 Filed Sep 26, 2018 19:43 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | OtherCommon Stock | 1,521,863 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-025346 · doc4.xml · nonDerivative · entry 1 Lopez Fabio · CIK 0001724449 · Former Director, 10% holder EQC Private Markets SAC Fund II Ltd-EQC Biotech Sely S Fund · CIK 0001724585 · 10% owner EQC Private Markets SAC Fund Ltd-EQC Biotech Sely I Fund · CIK 0001724529 · 10% owner EQC Private Markets SAC Fund Ltd-EQC Biotech Sely II Fund` · CIK 0001724530 · 10% owner Equilibria Capital Management Ltd · CIK 0001724701 · 10% owner Castilian Ltd. · CIK 0001724523 · 10% owner Varibobi Financial Holdings Ltd · CIK 0001724811 · 10% owner Tafur Daniel · CIK 0001724558 · 10% owner EQC Private Markets II SAC Fund Ltd-EQC Biotech Sely III Fund · CIK 0001724539 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: EQC Private Markets SAC Fund II Ltd-EQC Biotech Sely S Fund ("Sely S") distributed 1,521,863 shares to its partners on a pro rata basis, for no consideration. F2 · balance_after: As a partner of Sely S, Fabio Lopez, received 19,524 of the shares distributed by Sely S. Read SEC document |
| December 29, 2017 Filed Dec 29, 2017 17:10 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | GrantWarrant (Right to Buy) · Derivative | 316,163 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-067657 · doc4.xml · derivative · entry 8 Lopez Fabio · CIK 0001724449 · Director · 10% owner EQC Private Markets SAC Fund II Ltd-EQC Biotech Sely S Fund · CIK 0001724585 · 10% owner EQC Private Markets SAC Fund Ltd-EQC Biotech Sely I Fund · CIK 0001724529 · 10% owner EQC Private Markets SAC Fund Ltd-EQC Biotech Sely II Fund` · CIK 0001724530 · 10% owner EQC Private Markets II SAC Fund Ltd-EQC Biotech Sely III Fund · CIK 0001724539 · 10% owner Equilibria Capital Management Ltd · CIK 0001724701 · 10% owner Castilian Ltd. · CIK 0001724523 · 10% owner Varibobi Financial Holdings Ltd · CIK 0001724811 · 10% owner Tafur Daniel · CIK 0001724558 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Company Disclosed balance after: 316,163 Underlying: Common Stock · 316,163 shares Expires 2022-12-29 F9 · derivative.exercise_price: The exercise price per share for the warrant is equal to 105% of the volume weighted average price of the Issuer's common stock for the 30 calendar days following the closing date of the Merger. F10 · derivative.exercise_date: Immediately exercisable. F4 · ownership.nature: Shares held directly by EQC Private Markets SAC Fund Ltd EQC Biotech Sely I Fund, ("Sely I"), a Bermuda mutual fund company. Equilibria manages Sely I and may be deemed to beneficially hold shares held by such fund. Read SEC document |
| December 29, 2017 Filed Dec 29, 2017 17:10 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | GrantCommon Stock | 3,343 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-067657 · doc4.xml · nonDerivative · entry 7 Lopez Fabio · CIK 0001724449 · Director · 10% owner EQC Private Markets SAC Fund II Ltd-EQC Biotech Sely S Fund · CIK 0001724585 · 10% owner EQC Private Markets SAC Fund Ltd-EQC Biotech Sely I Fund · CIK 0001724529 · 10% owner EQC Private Markets SAC Fund Ltd-EQC Biotech Sely II Fund` · CIK 0001724530 · 10% owner EQC Private Markets II SAC Fund Ltd-EQC Biotech Sely III Fund · CIK 0001724539 · 10% owner Equilibria Capital Management Ltd · CIK 0001724701 · 10% owner Castilian Ltd. · CIK 0001724523 · 10% owner Varibobi Financial Holdings Ltd · CIK 0001724811 · 10% owner Tafur Daniel · CIK 0001724558 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Individual Disclosed balance after: 3,343 F1 · price: Received in exchange for common shares of SELLAS Life Sciences Group, Ltd ("SELLAS") in connection with the merger of SELLAS and a wholly owned indirect subsidiary of the Issuer (then known as Galena Biopharma, Inc.) (the "Merger"). On the effective date of the Merger, each common share of SELLAS was converted into 43.9972 shares of the Issuer's common stock. F8 · ownership.nature: Shares held directly by Daniel Tafur ("Mr. Tafur"). Mr. Tafur is chief investment officer, founder and board member of Equilibria and may be deemed to beneficially own shares beneficially owned by Equilibria. Mr. Tafur disclaims beneficial ownership of securities beneficially owned by Equilibria, except to the extent of any pecuniary interests therein. Read SEC document |
| December 29, 2017 Filed Dec 29, 2017 17:10 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | GrantCommon Stock | 3,343 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-067657 · doc4.xml · nonDerivative · entry 6 Lopez Fabio · CIK 0001724449 · Director · 10% owner EQC Private Markets SAC Fund II Ltd-EQC Biotech Sely S Fund · CIK 0001724585 · 10% owner EQC Private Markets SAC Fund Ltd-EQC Biotech Sely I Fund · CIK 0001724529 · 10% owner EQC Private Markets SAC Fund Ltd-EQC Biotech Sely II Fund` · CIK 0001724530 · 10% owner EQC Private Markets II SAC Fund Ltd-EQC Biotech Sely III Fund · CIK 0001724539 · 10% owner Equilibria Capital Management Ltd · CIK 0001724701 · 10% owner Castilian Ltd. · CIK 0001724523 · 10% owner Varibobi Financial Holdings Ltd · CIK 0001724811 · 10% owner Tafur Daniel · CIK 0001724558 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By limited liability company Disclosed balance after: 3,343 F1 · price: Received in exchange for common shares of SELLAS Life Sciences Group, Ltd ("SELLAS") in connection with the merger of SELLAS and a wholly owned indirect subsidiary of the Issuer (then known as Galena Biopharma, Inc.) (the "Merger"). On the effective date of the Merger, each common share of SELLAS was converted into 43.9972 shares of the Issuer's common stock. F7 · ownership.nature: Shares held by Varibobi Financial Holdings Limited, a Cyprus limited liability company ("Varibobi"). Varibobi is an owner of Equilibria and may be deemed to beneficially hold shares beneficially owned by Equilibria. Fabio Lopez is the sole owner of Varibobi and the chief executive officer and a board member of Equilibria and may be deemed to be the indirect beneficial owner of the shares owned by Varibobi and Equilibria. Mr. Lopez disclaims beneficial ownership of securities beneficially owned by Equilibria, except to the extent of any pecuniary interests therein. Read SEC document |
| December 29, 2017 Filed Dec 29, 2017 17:10 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | GrantCommon Stock | 58,208 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-067657 · doc4.xml · nonDerivative · entry 5 Lopez Fabio · CIK 0001724449 · Director · 10% owner EQC Private Markets SAC Fund II Ltd-EQC Biotech Sely S Fund · CIK 0001724585 · 10% owner EQC Private Markets SAC Fund Ltd-EQC Biotech Sely I Fund · CIK 0001724529 · 10% owner EQC Private Markets SAC Fund Ltd-EQC Biotech Sely II Fund` · CIK 0001724530 · 10% owner EQC Private Markets II SAC Fund Ltd-EQC Biotech Sely III Fund · CIK 0001724539 · 10% owner Equilibria Capital Management Ltd · CIK 0001724701 · 10% owner Castilian Ltd. · CIK 0001724523 · 10% owner Varibobi Financial Holdings Ltd · CIK 0001724811 · 10% owner Tafur Daniel · CIK 0001724558 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Company Disclosed balance after: 58,208 F1 · price: Received in exchange for common shares of SELLAS Life Sciences Group, Ltd ("SELLAS") in connection with the merger of SELLAS and a wholly owned indirect subsidiary of the Issuer (then known as Galena Biopharma, Inc.) (the "Merger"). On the effective date of the Merger, each common share of SELLAS was converted into 43.9972 shares of the Issuer's common stock. F6 · ownership.nature: Shares held directly by EQC Private Markets II SAC Fund Ltd EQC Biotech Sely III Fund ("Sely III"), a Bermuda mutual fund company. Equilibria manages Sely III and may be deemed to beneficially hold shares held by such fund. Read SEC document |
| December 29, 2017 Filed Dec 29, 2017 17:10 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | GrantCommon Stock | 325,799 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-067657 · doc4.xml · nonDerivative · entry 4 Lopez Fabio · CIK 0001724449 · Director · 10% owner EQC Private Markets SAC Fund II Ltd-EQC Biotech Sely S Fund · CIK 0001724585 · 10% owner EQC Private Markets SAC Fund Ltd-EQC Biotech Sely I Fund · CIK 0001724529 · 10% owner EQC Private Markets SAC Fund Ltd-EQC Biotech Sely II Fund` · CIK 0001724530 · 10% owner EQC Private Markets II SAC Fund Ltd-EQC Biotech Sely III Fund · CIK 0001724539 · 10% owner Equilibria Capital Management Ltd · CIK 0001724701 · 10% owner Castilian Ltd. · CIK 0001724523 · 10% owner Varibobi Financial Holdings Ltd · CIK 0001724811 · 10% owner Tafur Daniel · CIK 0001724558 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Company Disclosed balance after: 325,799 F1 · price: Received in exchange for common shares of SELLAS Life Sciences Group, Ltd ("SELLAS") in connection with the merger of SELLAS and a wholly owned indirect subsidiary of the Issuer (then known as Galena Biopharma, Inc.) (the "Merger"). On the effective date of the Merger, each common share of SELLAS was converted into 43.9972 shares of the Issuer's common stock. F5 · ownership.nature: Shares held directly by EQC Private Markets SAC Fund Ltd EQC Biotech Sely II Fund, ("Sely II"), a Bermuda mutual fund company. Equilibria manages Sely II and may be deemed to beneficially hold shares held by such fund. Read SEC document |
| December 29, 2017 Filed Dec 29, 2017 17:10 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | GrantCommon Stock | 676,324 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-067657 · doc4.xml · nonDerivative · entry 3 Lopez Fabio · CIK 0001724449 · Director · 10% owner EQC Private Markets SAC Fund II Ltd-EQC Biotech Sely S Fund · CIK 0001724585 · 10% owner EQC Private Markets SAC Fund Ltd-EQC Biotech Sely I Fund · CIK 0001724529 · 10% owner EQC Private Markets SAC Fund Ltd-EQC Biotech Sely II Fund` · CIK 0001724530 · 10% owner EQC Private Markets II SAC Fund Ltd-EQC Biotech Sely III Fund · CIK 0001724539 · 10% owner Equilibria Capital Management Ltd · CIK 0001724701 · 10% owner Castilian Ltd. · CIK 0001724523 · 10% owner Varibobi Financial Holdings Ltd · CIK 0001724811 · 10% owner Tafur Daniel · CIK 0001724558 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Company Disclosed balance after: 676,324 F1 · price: Received in exchange for common shares of SELLAS Life Sciences Group, Ltd ("SELLAS") in connection with the merger of SELLAS and a wholly owned indirect subsidiary of the Issuer (then known as Galena Biopharma, Inc.) (the "Merger"). On the effective date of the Merger, each common share of SELLAS was converted into 43.9972 shares of the Issuer's common stock. F4 · ownership.nature: Shares held directly by EQC Private Markets SAC Fund Ltd EQC Biotech Sely I Fund, ("Sely I"), a Bermuda mutual fund company. Equilibria manages Sely I and may be deemed to beneficially hold shares held by such fund. Read SEC document |
| December 29, 2017 Filed Dec 29, 2017 17:10 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | GrantCommon Stock | 1,521,863 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-067657 · doc4.xml · nonDerivative · entry 2 Lopez Fabio · CIK 0001724449 · Director · 10% owner EQC Private Markets SAC Fund II Ltd-EQC Biotech Sely S Fund · CIK 0001724585 · 10% owner EQC Private Markets SAC Fund Ltd-EQC Biotech Sely I Fund · CIK 0001724529 · 10% owner EQC Private Markets SAC Fund Ltd-EQC Biotech Sely II Fund` · CIK 0001724530 · 10% owner EQC Private Markets II SAC Fund Ltd-EQC Biotech Sely III Fund · CIK 0001724539 · 10% owner Equilibria Capital Management Ltd · CIK 0001724701 · 10% owner Castilian Ltd. · CIK 0001724523 · 10% owner Varibobi Financial Holdings Ltd · CIK 0001724811 · 10% owner Tafur Daniel · CIK 0001724558 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Company Disclosed balance after: 1,521,863 F1 · price: Received in exchange for common shares of SELLAS Life Sciences Group, Ltd ("SELLAS") in connection with the merger of SELLAS and a wholly owned indirect subsidiary of the Issuer (then known as Galena Biopharma, Inc.) (the "Merger"). On the effective date of the Merger, each common share of SELLAS was converted into 43.9972 shares of the Issuer's common stock. F3 · ownership.nature: Shares held directly by EQC Private Markets SAC Fund II Ltd EQC Biotech Sely S Fund ("Sely S"), a Bermuda mutual fund company. Equilibria manages Sely S and may be deemed to beneficially hold shares held by such fund. Read SEC document |
| December 29, 2017 Filed Dec 29, 2017 17:10 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | GrantCommon Stock | 149,766 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-067657 · doc4.xml · nonDerivative · entry 1 Lopez Fabio · CIK 0001724449 · Director · 10% owner EQC Private Markets SAC Fund II Ltd-EQC Biotech Sely S Fund · CIK 0001724585 · 10% owner EQC Private Markets SAC Fund Ltd-EQC Biotech Sely I Fund · CIK 0001724529 · 10% owner EQC Private Markets SAC Fund Ltd-EQC Biotech Sely II Fund` · CIK 0001724530 · 10% owner EQC Private Markets II SAC Fund Ltd-EQC Biotech Sely III Fund · CIK 0001724539 · 10% owner Equilibria Capital Management Ltd · CIK 0001724701 · 10% owner Castilian Ltd. · CIK 0001724523 · 10% owner Varibobi Financial Holdings Ltd · CIK 0001724811 · 10% owner Tafur Daniel · CIK 0001724558 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By limited liability company Disclosed balance after: 149,766 F1 · price: Received in exchange for common shares of SELLAS Life Sciences Group, Ltd ("SELLAS") in connection with the merger of SELLAS and a wholly owned indirect subsidiary of the Issuer (then known as Galena Biopharma, Inc.) (the "Merger"). On the effective date of the Merger, each common share of SELLAS was converted into 43.9972 shares of the Issuer's common stock. F2 · ownership.nature: Shares held directly by Equilibria Capital Management Limited ("Equilibria"), a Bermuda limited liability company. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.